🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

Gilead Sciences cell therapy unit can grow to multi-billion dollar business by end of 2023 - BMO Capital

Published 16/05/2023, 14:30
©  Reuters
GILD
-

BMO Capital analysts upgraded Gilead Sciences (NASDAQ:GILD) to Outperform from Market Perform, raising the price target to $100 per share from $90 in a note Tuesday.

The analysts pointed to three key factors for the upgrade, which were the company's best-in-class cell therapy franchise, an improving solid tumor oncology business, and durable growth anchored by the HIV/Virology business.

They stated that Gilead's cell therapy business has the potential to grow into a multi-billion dollar business by YE2023.

"Core to our revised view of GILD shares is the strong and growing cell therapy business anchored by Yescarta and Tecartus. We highlight the company's strong manufacturing capabilities as a key differentiator from competition in the CD-19 targeting CART space," they wrote.

"Gilead's traditional oncology franchise is starting to get its footing with Trodelvy as the anchor," the analysts continued, adding that "HIV/Virology, Gilead's perennial performer will continue to dominate as the business now starts to see its next leg of growth materialize."

"We think continued growth of the Cell Tx business, coupled with pipeline success could lead to multiple expansion," they concluded.

 

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.